Could a Three-Drug cocktail outsmart recurrent breast cancer?
NCT ID NCT06976944
First seen Feb 25, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This study is for people with a type of breast cancer called triple-negative that has come back after initial treatment. The researchers want to see if adding a drug called bevacizumab to the standard combination of pembrolizumab and paclitaxel can help control the cancer longer. About 44 participants will receive either the two-drug or three-drug regimen, and the study will track how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akita University Hospital
NOT_YET_RECRUITINGAkita, Akita, 010-8543, Japan
Contact Phone: •••-•••-••••
Contact
-
Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-••••
Contact
-
Gifu University Hospital
RECRUITINGGifu, Gifu, 501-1194, Japan
Contact Phone: •••-•••-••••
Contact
-
Hiroshima University Hospital
RECRUITINGHiroshima, Hiroshima, 734-8551, Japan
Contact Phone: •••-•••-••••
Contact
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
Contact Phone: •••-•••-••••
Contact
-
Hyogo Cancer Center
RECRUITINGAkashi-shi, Hyōgo, 673-8558, Japan
Contact Phone: •••-•••-••••
Contact
-
Kindai University Hospital
RECRUITINGSakai-shi, Osaka, 590-0197, Japan
Contact Phone: •••-•••-••••
Contact
-
Nagoya City University Hospital
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
Contact Phone: •••-•••-••••
Contact
-
Nagoya University Hospital
RECRUITINGNagoya, Aichi-ken, 466-8560, Japan
Contact Phone: •••-•••-••••
Contact
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
Contact Phone: •••-•••-••••
Contact
-
National Hospital Organization Nagoya Medical Center
RECRUITINGNagoya, Aichi-ken, 460-0001, Japan
Contact Phone: •••-•••-••••
Contact
-
Okayama University Hospital
RECRUITINGOkayama, Okayama-ken, 700-8558, Japan
Contact Phone: •••-•••-••••
Contact
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, 541-8567, Japan
Contact Phone: •••-•••-••••
Contact
-
Osaka Metropolitan University Hospital
RECRUITINGOsaka, Osaka, 545-0051, Japan
Contact Phone: •••-•••-••••
Contact
-
SHOWA Medical University Hospital
RECRUITINGShinagawa-ku, Tokyo, 142-8666, Japan
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.